SYK Inhibitors
1 drugsAbout SYK
Spleen tyrosine kinase (SYK) is an intracellular non-receptor tyrosine kinase crucial for signal transduction in hematopoietic cells. It plays a key role in immune cell development, activation, and function through various signaling pathways.
SYK's involvement in critical cellular processes makes it a compelling target for drug development, particularly in immune-related disorders. Currently, there is no genetic evidence directly linking SYK to specific diseases.
SYK is targeted by one FDA-approved drug, TAVALISSE, a small molecule used in 'other' therapeutic areas. Rigel Pharmaceuticals is the sole company with an approved SYK-targeting drug.
Top SYK Drugs
Rigel Pharmaceuticals is the only company with an approved drug targeting SYK.
Low competition suggests an opportunity for other companies to enter the SYK inhibitor market.
SYK Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets SYK, using small molecule modality.
The lack of diverse modalities indicates a whitespace opportunity for antibody or protein-based therapeutics.
SYK Clinical Trials 54 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on SYK. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 21 | 17 | 0 | 4 | 100% |
| Phase 2 | 23 | 11 | 11 | 1 | 50% |
| Phase 3 | 10 | 8 | 1 | 1 | 89% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
SYK Drug Approval Timeline (2018 - 2018)
The first and only drug, TAVALISSE, was approved in 2018.
Recent entry suggests potential for further drug development, but also possible market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 13 (2 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on SYK. A trial counts if an approved drug acting on SYK is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.